Q3’25 Investor Survey: What are Investors Most Concerned About?
- Regulatory & Legislative Barriers
- Commercialisation & Commercial Viability
- Safety & Ethics
- Political Uncertainty
- Trial Outcomes & Development Timelines
- Return on Investment
- Stigma
- Big Pharma Interference
- Bankruptcy & Company Execution
- Funding (Sources & Uses)
- Next: What are Psychedelics Investors Concerned About?
Earlier, we shared the high-level results of our Q3’25 Psychedelic Investor Survey, our fourth such survey. Here, we take a closer look at investors’ qualitative responses to provide a better picture of their key areas of excitement. (We will explore key areas of concern in our third and final article detailing these survey results.)
In general, investor enthusiasm for bringing psychedelic therapies to market remains strong, but regulatory hurdles continue to be the dominant concern. Additionally, although most investors view changes in the U.S. administration positively, a growing share cites political uncertainty as a concern.
At the same time, attention is shifting toward commercial viability after approval: investors increasingly worry about rollout challenges, infrastructure and workforce gaps, and uncertain reimbursement pathways. Conversely, anxiety about trial outcomes and development timelines has abated, likely buoyed by several positive readouts since the start of 2025.
Regulatory & Legislative Barriers
As mentioned, these perceived barriers and challenges continue to loom large among investors of all stripes, despite many viewing the current U.S. administration as being more amenable to psychedelic therapies.
It’s quite simple, really: investors cited potential regulatory headwinds, bureaucracy, and hurdles, predominantly in the pre-approval environment, as well as in the review of a new drug application...
Join Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.
- Regular Bulletins featuring news, analysis, and research
- Articles and deep dives across psychedelic drug development, policy, and research
- Exclusive interviews with researchers, executives, and policymakers
- Bespoke resources and tools including the Psychedelic Bill Tracker
- Quarterly video briefings and slide decks